De-escalation of radiation therapy in patients with stage I, node-negative, HER2-positive breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33767168/
In the modern era, highly effective anti-HER2 therapy is associated with low local-regional recurrence (LRR) rates for early-stage HER2+ breast cancer raising the question of whether local therapy de-escalation by...
![[Full text] Association of ET and Dementia in Women with Breast Cancer | BCTT](https://static-content-prd.skipta.com/public/skipta/skipta-post/2023-02/og_logo_8.png "[Full text] Association of ET and Dementia in Women with Breast Cancer | BCTT"){kind=logo}
[Full text] Association of ET and Dementia in Women with Breast Cancer | BCTT
Globally, breast cancer is the most common type of cancer diagnosed in women with over 270,000 new cases estimated in 2020 in the United States alone. However, despite this high...
AKT Somatic Mutations in Chinese Breast Cancer Patients | CMAR
Lingzhu Wen, 1, * Guochun Zhang, 1, * Chongyang Ren, 1, * Xuerui Li, 1 Hsiaopei Mok, 1 Minghan Jia, 1 Yulei Wang, 1 Bo Chen, 1 Kai Li, 1...
The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33767780/
The use of the PARP inhibitors (PARPi) in the treatment of breast cancer (BC) with germine mutations has evolved over the years, and further research has been done in order...
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
Source : https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-021-01415-w
Background Circulating tumor cells (CTCs) are prognostic in patients with advanced breast cancer (ABC). However, no data exist about their use in patients treated with palbociclib. We analyzed the prognostic...